Happen to have a spare $750,000 USD in your bank account? If so, you could afford the initial year of treatment on Biogen’s new spinal muscular atrophy drug, Spinraza. After the first year, you’d need another $375,000 per year for subsequent treatment. Our collective wallets shuddered just thinking about that. Keep in mind—this is a drug for an ultra-orphan disease so companies typically set high price points given the small patient populations. Nonetheless, the price tag is turning heads in the media. Patients and their families will be waiting with bated breath to gauge payers’ reactions. So far into 2017, it looks like there is no end in sight for drug pricing controversies.